Document Detail

Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.
MedLine Citation:
PMID:  11181998     Owner:  NLM     Status:  MEDLINE    
In the period 1989-1991, 612 patients with inoperable stage IIIA/B and IV non-small cell lung cancer (NSCLC) were randomized in a phase III trial comparing three chemotherapy regimens. Survival data at five and six years of follow-up confirm the overall benefit of treatment with a combination of vinorelbine and cisplatin compared to vindesine plus cisplatin or vinorelbine alone. Of the 612 patients randomized at the start of the study, 17 have survived beyond five years. Of these patients, eight had entered the trial with metastatic disease. Multivariate analysis to detect prognostic factors suggested a possible interaction between the effect of having cisplatin in the chemotherapy received and baseline performance status. Subgroup analysis subsequently confirmed that the survival benefit of the vinorelbine plus chemotherapy regimen is evident only in patients with initial World Health Organization performance status (PS) of 0-1. Among these patients, the one-year survival rate is 38% for the vinorelbine/cisplatin arm, 29% for vindesine/cisplatin and 34% for vinorelbine alone. The corresponding figures for median survival are 43, 33 and 36 weeks. Among inoperable NSCLC patients with a PS of 2, who appear from this trial not to have benefited from the presence of cisplatin in their chemotherapy, use of single agent vinorelbine is an appropriate treatment option.
T Le Chevalier; D Brisgand; J C Soria; J Y Douillard; J L Pujol; P Ruffie; V Aberola; S Cigolari
Related Documents :
3755988 - Cisplatin sensitization to radiotherapy in stage iv squamous cell carcinoma of the head...
21450438 - Appropriate liver resection type for patients with the american joint committee on canc...
10928138 - Cisplatin, vindesine, mitomycin-c and 13-cis retinoic acid in the treatment of advanced...
1942548 - Phase ii evaluation of combined cisplatin and vindesine in advanced squamous cell carci...
2487178 - Psychoses in twins. a 10 year clinical and biochemical follow-up study.
24606478 - Goseki grade and tumour location influence survival of patients with gastric cancer.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The oncologist     Volume:  6 Suppl 1     ISSN:  1083-7159     ISO Abbreviation:  Oncologist     Publication Date:  2001  
Date Detail:
Created Date:  2001-02-22     Completed Date:  2001-04-05     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9607837     Medline TA:  Oncologist     Country:  United States    
Other Details:
Languages:  eng     Pagination:  8-11     Citation Subset:  IM    
Institut Gustave-Roussy, Villejuif Cedex, France. tle-che!
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / administration & dosage,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Cisplatin / administration & dosage
Lung Neoplasms / drug therapy*,  pathology
Middle Aged
Survival Analysis
Treatment Outcome
Vinblastine / administration & dosage,  analogs & derivatives*,  therapeutic use*
Vindesine / administration & dosage
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 15663-27-1/Cisplatin; 53643-48-4/Vindesine; 71486-22-1/vinorelbine; 865-21-4/Vinblastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly pa...
Next Document:  Carboplatin and vinorelbine in advanced non-small cell lung cancer: a phase I/II study.